THERMO FISHER CELL AND GENE ONLINE LIVE EVENTS
2025 CGT Regulatory Outlook
As the cell and gene therapy landscape continues to rapidly evolve, with over 450 unique products in clinical development and 50 approvals expected by 2030, understanding the regulatory environment is crucial for stakeholders across the industry. Cell & Gene Live focu...
Unlocking The Future Of Allogeneic Cell Therapy For Oncology
Hear from experts in the cell and gene therapy space about their shared insights into potential trends driving the future of allogeneic therapies for oncology.
2024 Regulatory Outlook With FDA's Drs. Peter Marks And Nicole Verdun
Explore the evolving regulatory landscape for cell and gene therapies in 2024 including the increasing speed availability of cell and gene therapies by enabling manufacturing processes and standards development.
mRNA For Cancer Immunotherapy: 2024 Outlook
As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.
Stability To Scalability: The Future Of Viral Vector Therapies
Despite advances that have contributed to improvements in viral vector yields, innovation is still needed in the CGT sector to impact product quality and accelerate scale for viral vector production.
Driving Down COGS: Automation's Role In Cell Therapy Manufacturing
Process automation, task automation, and test automation have become crucial components of cell therapy manufacturing. Improve your cell therapy manufacturing costs and scalability via standardization and automation.
Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments
Listen in to this expert discussion on problems in the cell and gene therapy industry, specific FDA initiatives to overcome these, broader regulatory trends, and more.